Core Insights - OrthoPediatrics reported a revenue of $52.67 million for the quarter ended December 2024, reflecting a 40% increase year-over-year [1] - The earnings per share (EPS) was -$0.29, a decline from -$0.23 in the same quarter last year, with an EPS surprise of -31.82% compared to the consensus estimate of -$0.22 [1] - The revenue reported was slightly below the Zacks Consensus Estimate of $52.7 million, resulting in a surprise of -0.06% [1] Revenue Performance - Trauma and deformity product sales reached $36.41 million, exceeding the average estimate of $35.25 million, marking a year-over-year increase of 34.5% [4] - Sports medicine/other product sales were $0.63 million, falling short of the $1.12 million average estimate, representing a year-over-year decline of 29.2% [4] - Scoliosis product sales amounted to $15.63 million, surpassing the estimated $12.86 million, with a significant year-over-year increase of 61.8% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.7%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - OrthoPediatrics reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, marking an earnings surprise of -31.82% [1] Financial Performance - The company posted revenues of $52.67 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.06%, but showing an increase from $37.61 million in the same quarter last year [2] - Over the last four quarters, OrthoPediatrics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - OrthoPediatrics shares have lost about 0.1% since the beginning of the year, compared to a decline of -0.5% for the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $52.47 million, and for the current fiscal year, it is -$0.86 on revenues of $239.3 million [7] - The trend of estimate revisions for OrthoPediatrics is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Instruments industry, to which OrthoPediatrics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Revenue Announcement - OrthoPediatrics Corp. announced preliminary unaudited net revenue for Q4 2024 and the full year ended December 31, 2024[4]. - The company provided management's projection for 2025 net revenue, indicating potential growth[4]. Financial Status - The financial information is preliminary and subject to change pending the completion of the audit process[6].

Core Viewpoint - OrthoPediatrics Corp. reported record financial results for the full year 2024, with total revenue of $204.7 million, a 38% increase from the previous year, and significant growth in adjusted EBITDA, indicating strong operational performance and market position in pediatric orthopedics [1][5][15]. Financial Performance - Total revenue for Q4 2024 was $52.7 million, a 40% increase from $37.6 million in Q4 2023, driven by growth in Global Trauma and Deformity, Scoliosis, and OPSB segments [4][7]. - Full year 2024 revenue reached $204.7 million, up 38% from $148.7 million in 2023, with U.S. revenue increasing by 45% to $161.2 million [5][7]. - Adjusted EBITDA for Q4 2024 was $3.0 million, compared to $1.3 million in Q4 2023, while full year adjusted EBITDA was $8.5 million, up from $5.0 million in 2023 [15][16]. Revenue Breakdown - U.S. revenue for Q4 2024 was $42.9 million, a 52% increase from $28.3 million in Q4 2023, representing 81% of total revenue [4][31]. - International revenue for Q4 2024 was $9.8 million, a 5% increase from $9.4 million in Q4 2023, accounting for 19% of total revenue [4][31]. - Trauma and Deformity revenue for Q4 2024 was $36.4 million, a 35% increase from $27.1 million in Q4 2023, while Scoliosis revenue increased by 62% to $15.6 million [6][31]. Operating Expenses - Total operating expenses for Q4 2024 were $49.6 million, a $14.8 million increase from $34.8 million in Q4 2023, primarily due to increased sales volume and the addition of Boston O&P [10][12]. - Sales and marketing expenses rose by 31.1% to $16.8 million in Q4 2024, while general and administrative expenses increased by 28.2% to $24.4 million [11][12]. Net Loss and Cash Flow - Net loss for Q4 2024 was $16.1 million, compared to a net loss of $6.7 million in Q4 2023, with net loss per share of $0.69 [15][16]. - The company reduced free cash flow usage by 70% in Q4 2024 compared to the third quarter of 2024, anticipating the first full quarter of positive free cash flow in Q4 2025 [7][15]. Future Guidance - For full year 2025, the company expects revenue to be in the range of $235.0 million to $242.0 million, representing growth of 15% to 18% compared to 2024 [18].

Core Insights - SOUR PATCH KIDS has launched a new product, Strawberry-Watermelon Glow Ups, which is the first gummy candy that glows under blacklight, featuring edible confetti made with turmeric extract [1][2] - The product aims to provide a multi-sensory experience beyond just taste, appealing to adventurous candy consumers [3] - SOUR PATCH KIDS Glow Ups will be available online on March 5th and at major retailers later in March, with a suggested retail price of $1.24 for a 3.08 oz bag and $2.98 for a 6.7 oz bag [5] Product Features - The Glow Ups are coated with flavorless turmeric extract confetti that emits a fluorescent glow under blacklight, allowing the strawberry-watermelon flavor to be the main focus [2] - The candy is designed for various events, enhancing experiences at concerts, gaming marathons, and movie nights [3] Marketing and Engagement - An exclusive Snapchat filter will be introduced, enabling users to experience the glow through augmented reality without needing a blacklight [4] - The product is positioned as a fun treat for social occasions, encouraging sharing and interaction among friends [3] Company Overview - Mondelēz International reported net revenues of approximately $36.4 billion in 2024, with a portfolio that includes iconic brands like Oreo, Ritz, and Cadbury [7]

Company Overview - OrthoPediatrics Corp. is focused exclusively on advancing pediatric orthopedics, offering over 75 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [3] - The company was founded in 2006 and has a global sales organization that distributes products in the United States and over 70 countries [3] Financial Results Announcement - OrthoPediatrics is scheduled to release its fourth quarter and full year 2024 financial results on March 4, 2025, after market close [1] - A conference call will be held on the same day at 4:30 p.m. ET to discuss the financial results [1] Investor Information - Investors can access a live and archived webcast of the conference call on the company's website, which will be available for replay for at least 90 days [2]

Core Insights - OrthoPediatrics Corp. has gained distribution rights to introduce additional bracing solutions in the US market through its OrthoPediatrics Specialty Bracing (OPSB) division [1][2] Company Overview - OrthoPediatrics is dedicated to advancing pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions [3] - The company currently markets over 70 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [3] - OrthoPediatrics distributes its products in the United States and over 70 countries globally [3] New Product Offerings - The OPSB division has established a distribution agreement with Thrive Orthopedics LLC, focusing on three pediatric orthotic solutions [2] - The Thrive Orthopedics F3 Hero Pediatric AFO is a lightweight carbon fiber ankle foot orthosis designed to improve walking stability while allowing flexibility [2] - The TruStretch Pediatric Equinus Brace provides optimal stretching for children with equinus deformity [2] - The Thrive Pediatric X-Glide Carbon Fiber Insoles are available in both rigid and flexible styles for gait training [2] Leadership Commentary - Joe Hauser, President of the OPSB division, expressed pride in the advancements made to help children with non-operative care and highlighted the distribution agreement as a significant step in the company's growth strategy [3]

Core Insights - OrthoPediatrics Corp. achieved record full year 2024 revenue of $205 million, reflecting a 38% year-over-year growth compared to $148.7 million in 2023 [1][6] - The company projects 2025 revenue to be between $235 million and $242 million, indicating a growth of 15% to 18% compared to 2024 [3] - OrthoPediatrics expects to generate adjusted EBITDA of $15 million to $17 million for the full year 2025 [3] 2024 Business and Financial Highlights - The company helped over 34,000 children in Q4 2024, totaling over 1.1 million children since inception [6] - Preliminary unaudited Q4 2024 net revenue reached $52.7 million, a 40% increase from $37.6 million in Q4 2023 [6] - Domestic Q4 2024 net revenue is expected to be $42.9 million, representing a 52% growth year-over-year, while international net revenue is projected at $9.8 million, a 5% increase [6] Strategic Initiatives - The Trauma and Deformity and Scoliosis businesses are key contributors to the company's growth, with a strong performance in the specialty bracing (OPSB) business [4] - The company aims to expand and scale its OPSB business, viewing it as a significant market opportunity and a strategic catalyst for growth [4] - OrthoPediatrics plans to release detailed Q4 and full year 2024 financial results in early March, with preliminary figures subject to adjustment [4]

Core Insights - OrthoPediatrics Corp. achieved record full year 2024 revenue of $205 million, reflecting a 38% year-over-year growth [1][6] - The company initiated guidance for adjusted EBITDA in 2025, projecting between $15 million to $17 million [3][4] 2024 Business and Financial Highlights - The preliminary unaudited full year 2024 net revenue is $204.7 million, up from $148.7 million in 2023, marking a 38% increase [6] - Domestic net revenue for 2024 is expected to be $161.1 million, representing a 45% annual growth, while international net revenue is projected at $43.6 million, a 16% annual growth [6] - In Q4 2024, the company generated preliminary unaudited net revenue of $52.7 million, a 40% increase from $37.6 million in Q4 2023 [6] - Domestic Q4 net revenue is expected to be $42.9 million, reflecting a 52% growth year-over-year, while international net revenue is projected at $9.8 million, a 5% increase [6] 2025 Financial Guidance - OrthoPediatrics projects 2025 revenue to be between $235 million and $242 million, indicating a growth of 15% to 18% compared to 2024 [3] - The company anticipates annual set deployment to be approximately $15 million [3] Strategic Initiatives and Market Position - The company continues to grow its market share in pediatric orthopedics, with strong performance in its Trauma and Deformity and Scoliosis businesses [4] - The specialty bracing business has been identified as a significant market opportunity, with plans for expansion and scaling in the coming years [4] Company Overview - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 70 products across trauma and deformity, scoliosis, and sports medicine categories [10] - The company distributes its products in the U.S. and over 70 countries globally [10]

WARSAW, Ind., Jan. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the rapid expansion of its Specialty Bracing (OPSB) division with entrance into 3 target markets within Indiana, Colorado, and Florida. Each of these new locations broadens the Company’s position in targeted geographies to partner with pediatric orthopedic surgeons in the region to treat chil ...